Are tesamorelin and sermorelin both currently marketed FDA-approved products?

Tesamorelin has a current labeled indication. FDA placed former Geref sermorelin products on its discontinued list and found they were not withdrawn for safety or effectiveness reasons.

Did the two drugs have the same clinical indication?

No. Tesamorelin's indication is excess abdominal fat in adults with HIV and lipodystrophy. Historical sermorelin evidence concerned pediatric growth hormone deficiency and growth response.

Does FDA's sermorelin discontinuation finding approve compounded products?

No. FDA's finding addresses the historical Geref products; compounded products are not FDA-approved and cannot inherit Geref's approval or the tesamorelin trial results.

Tesamorelin vs Sermorelin: FDA History

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Same receptor family, different clinical histories

Tesamorelin is a GHRH analog with a current FDA label for reducing excess abdominal fat in adults with HIV and lipodystrophy. Its pivotal randomized studies measured VAT, not general weight loss or anti-aging. Long-term cardiovascular safety remains unestablished in labeling. FDA prescribing information; Falutz et al., 2007, PMID 18057338.

Sermorelin is a shorter GHRH fragment. A historical multicenter open-label study of 110 previously untreated prepubertal children with GH deficiency reported increased height velocity; 86 children were eligible for efficacy analysis. That pediatric study does not test adult VAT reduction or directly compare sermorelin with tesamorelin. Geref International Study Group, 1996, PMID 8772599.

Question	Tesamorelin	Sermorelin
Evidence grade for cited outcome	High for VAT reduction in indicated adults	Low to moderate for historical pediatric growth response; open-label design limits inference
Studied population	Adults with HIV and excess abdominal fat	Children with GH deficiency
FDA product history	Currently labeled for the stated indication	Historical Geref products are on FDA’s discontinued list
Safety inference	Label warnings and unknown long-term cardiovascular safety	Discontinuation was not for safety or effectiveness; that is not a blanket safety finding

In 2013 FDA determined the former Geref products were not withdrawn for reasons of safety or effectiveness and kept them on the Orange Book’s discontinued list. That finding should not be recast as proof that sermorelin was unsafe, still marketed as Geref, or that a compounded preparation is FDA approved. FDA Federal Register determination, 2013; FDA on compounded drugs.

The cited records offer no head-to-head efficacy ranking or validated combination claim. Trial outcomes in different ages and indications cannot be compared as if they share a patient population.

Educational comparison only; not medical advice.

Tesamorelin vs Sermorelin

Tesamorelin

Sermorelin

Same receptor family, different clinical histories

View Full Dossiers

Stay Updated on Peptide Comparisons